Table 4

Chemotherapy or immunosuppressive treatment in PML patients without hematopoietic stem cell transplantation
Patient Age Sex Underlying disease Chemotherapeutic or immunosuppressive agents
9 78 M Non-Hodgkin's lymphoma CPA, THP, VDS, PSL, R
10 66 M Non-Hodgkin's lymphoma CPA, DXR, VCR, PSL, R
11 72 F Non-Hodgkin's lymphoma CPA, DXR, VCR, PSL, THP, R
12 64 F Non-Hodgkin's lymphoma CPA, DXR, VCR, PSL, ETP
13 77 M Adult T-cell leukemia CPA, DXR, VCR, PSL
14 64 M Multiple myeloma DEX, DXR, VCR, Bzb
15 67 M Chronic lymphocytic leukemia CPA
16 71 M Primary macroglobulinemia R
17 62 M Non-Hodgkin's lymphoma NA
18 22 M Primary immunodeficiency syndrome NA
19 24 M Primary immunodeficiency syndrome NA

M, male; F, female; CPA, cyclophosphamide; THP, pirarubicin; VDS, vindesine; PSL, prednisolone; R, rituximab; DXR, doxorubicin; VCR, vincristine; ETP, etoposide; DEX, dexamethasone; Bzb, bortezomib; NA, not administered.

Nakamichi et al.

Nakamichi et al. BMC Neurology 2012 12:121   doi:10.1186/1471-2377-12-121

Open Data